GSK to Acquire US Lung Cancer Drug Firm Nuvalent for $8 Billion

GSK is acquiring US lung cancer drug specialist Nuvalent for $8 billion, aiming to expand its oncology portfolio. This marks GSK's largest deal in over a decade and an early success for CEO Miels.